Back to Search Start Over

Hemoglobin, anemia, and clinical outcomes in vericiguat global study in subjects with heart failure with reduced ejection fraction (VICTORIA)

Authors :
Ciaran McMullan
Yinggan Zheng
Adrian F. Hernandez
C.S.P Lam
A. A. Voors
Vojtech Melenovsky
Piotr Ponikowski
Javed Butler
Lothar Roessig
Christopher M. O'Connor
Justin A. Ezekowitz
Alain Cohen-Solal
Burkert Pieske
Paul W. Armstrong
Jorge Escobedo
Source :
Web of Science
Publication Year :
2021
Publisher :
Oxford University Press (OUP), 2021.

Abstract

Background In the VICTORIA trial of patients with HFrEF after a worsening HF event, anemia occurred more often in patients treated with vericiguat (7.6%) compared with placebo (5.7%). We explored the association between vericiguat, baseline hemoglobin, and anemia and also whether hemoglobin was related to the benefit of vericiguat in HF. Methods Anemia was defined as a hemoglobin Results Of 4812 patients with baseline hemoglobin data available, 1719 (35.7%) were WHO anemic; median hemoglobin was 13.4 g/dL (IQR 12.1 to 14.7 g/dL). In total, 1643 patients had WHO anemia at 16 weeks (of which 284 were new from baseline for vericiguat and 219 for placebo) and this occurred more often in the vericiguat group than the placebo group (P Conclusions Anemia was present at baseline in over one-third of patients in the VICTORIA trial and was generally mild. Lower hemoglobin was associated with greater frequency of clinical events. Although vericiguat modestly lowered hemoglobin by 16 weeks, this effect did not further progress nor influence the association of benefit of vericiguat. Funding Acknowledgement Type of funding sources: Other. Main funding source(s): Merck & Co., Inc. and Bayer

Details

ISSN :
15229645 and 0195668X
Volume :
42
Database :
OpenAIRE
Journal :
European Heart Journal
Accession number :
edsair.doi.dedup.....f2f31502a561adae034fec9e742aa7fb